Una comparación entre los estudios de fase 3 y un estudio de fase 4 de nalmefeno en el trastorno por uso de alcohol. ¿Existen diferencias?
Resumen
Palabras clave
Referencias
Barrio, P., Ortega, L., Guardia, J., Roncero, C., Yuguero, L. y Gual, A. (2018). Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results. Clinical Drug Investigation, 38, 147-155. doi:10.1007/s40261-017-0590-4.
Dekkers, O. M., von Elm, E., Algra, A., Romijn, J. A. y Vandenbroucke, J. P. (2010). How to assess the external validity of therapeutic trials: a conceptual approach. International Journal of Epidemiology, 39, 89–94. doi:10.1093/ije/dyp174.
Farahani, P., Levine, M., Gaebel, K. y Thabane, L. (2005). Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis. The Canadian Journal of Clinical Pharmacology, 12, e254-263.
Fein, G. (2015). Psychiatric Comorbidity in Alcohol Dependence. Neuropsychology Review, 25, 456–475. doi:10.1007/s11065-015-9304-y.
Flensborg-Madsen, T., Mortensen, E. L., Knop, J., Becker, U., Sher, L. y Grønbæk, M. (2009). Comorbidity and temporal ordering of alcohol use disorders and other psychiatric disorders: results from a Danish register-based study. Comprehensive Psychiatry, 50, 307–314. doi:10.1016/j.comppsych.2008.09.003.
Gual, A., He, Y., Torup, L., van den Brink, W., Mann, K. y ESENSE 2 Study Group. (2013). A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. European Neuropsychopharmacology, 23, 1432–1442. doi:10.1016/j.euroneuro.2013.02.006.
Hoertel, N., de Maricourt, P., Katz, J., Doukhan, R., Lavaud, P., Peyre, H. y Limosin, F. (2014). Are participants in pharmacological and psychotherapy treatment trials for social anxiety disorder representative of patients in real-life settings? Journal of Clinical Psychopharmacology, 34, 697–703. doi:10.1097/JCP.0000000000000204.
Linden, M. (1984). Phase-IV Research: Specifics, Objectives and Methodology. Pharmacopsychiatry, 17, 140–142. doi:10.1055/s-2007-1017425.
Mann, K., Bladström, A., Torup, L., Gual, A. y van den Brink, W. (2013). Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biological Psychiatry, 73, 706–713. doi:10.1016/j.biopsych.2012.10.020.
Pearson, M. y Coomber, R. (2010). The challenge of external validity in policy-relevant systematic reviews: a case study from the field of substance misuse. Addiction, 105, 136–145. doi:10.1111/j.1360-0443.2009.02713.x.
Persaud, N. y Mamdani, M. M. (2006). External validity: the neglected dimension in evidence ranking. Journal of Evaluation in Clinical Practice, 12, 450–453. doi:10.1111/j.1365-2753.2006.00730.x.
Rothwell, P. M. (2005). External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet, 365, 82–93. doi:10.1016/S0140-6736(04)17670-8.
Uijen, A. A., Bakx, J. C., Mokkink, H. G. A. y van Weel, C. (2007). Hypertension patients participating in trials differ in many aspects from patients treated in general practices. Journal of Clinical Epidemiology, 60, 330–335. doi:10.1016/j.jclinepi.2006.05.015.
van den Brink, W., Aubin, H. J., Bladstrom, A., Torup, L., Gual, A. y Mann, K. (2013). Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol and Alcoholism, 48, 570–578. doi:10.1093/alcalc/agt061.
van den Brink, W., Sørensen, P., Torup, L., Mann, K., Gual, A. y SENSE Study Group. (2014). Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. Journal of Psychopharmacology, 28, 733–744. doi:10.1177/0269881114527362.
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E.,… Vos, T. (2013). Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet, 382, 1575–1586. doi:10.1016/S0140-6736(13)61611-6.
DOI: https://doi.org/10.20882/adicciones.1046
Enlaces refback
- No hay ningún enlace refback.